10x Genomics, Inc.
10x Genomics (TXG) reported Q2 2026 revenue of $151.0 million, up 3% YoY excluding non-recurring patent settlement revenue. Gross margin was 74%. FY2026 revenue guidance is $610 million to $630 million. Booked Atera orders exceed the 2026 shipment target of 40 units, with capacity as the constraint. Net loss was $17.9 million.
10x Genomics director John Stuelpnagel sold $1.155m of TXG Class A shares on Aug 11, 2026, selling 20,000 shares at $57.5812 to $58.725. After the trades, he beneficially owned 348,436 shares. The article also cites TXG Q2 2026 results and a Canaccord price target raised to $60.
Investing.com reports Cathie Wood’s ARK ETFs published Thursday trades. ARK bought 106,941 shares of Cerebras Systems (CBRS) for about $28.0M and bought Securitize (SECZ) and Perceptive Capital Solutions (FRNM). It sold Shopify (SHOP) 57,045 shares for about $8.6M and sold Palantir (PLTR) for about $7.5M, plus other smaller trades.
Over the past 7 days, alphai's AI scored 6 news stories mentioning TXG (10x Genomics, Inc.). Coverage has skewed bullish: 2 bullish, 3 neutral, and 1 bearish.
Recent TXG coverage spans earnings, financial news and insider activity.
In the last 30 days, TXG insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($1.2M). The most active reporter was STUELPNAGEL JOHN R with 2 filings.
Guidance raise plus Atera order strength is a near-term positive, but management flagged a modest Q3 sequential decline from transition dynamics and capacity constraints.
Insider selling is a modest, near-term sentiment signal, but it is not tied to new fundamentals in the text.
The sale is a modest negative flow signal for TXG, but it is not linked to new TXG fundamentals in the article.
The filing is a routine insider sale with no stated operational or guidance catalyst, so near-term price impact is likely limited.
Guidance raise plus demand commentary is a fresh fundamental catalyst supporting momentum.
alphai scores every news story that mentions TXG with an AI model for sentiment and relevance, and aggregates insider trades from 10x Genomics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
10x Genomics (TXG) reported Q2 2026 revenue of $151.0 million, up 3% YoY excluding non-recurring patent settlement revenue. Gross margin was 74%. FY2026 revenue guidance is $610 million to $630 million. Booked Atera orders exceed the 2026 shipment target of 40 units, with capacity as the constraint. Net loss was $17.9 million.
10 min read10x Genomics director John Stuelpnagel sold $1.155m of TXG Class A shares on Aug 11, 2026, selling 20,000 shares at $57.5812 to $58.725. After the trades, he beneficially owned 348,436 shares. The article also cites TXG Q2 2026 results and a Canaccord price target raised to $60.
2 min readInvesting.com reports Cathie Wood’s ARK ETFs published Thursday trades. ARK bought 106,941 shares of Cerebras Systems (CBRS) for about $28.0M and bought Securitize (SECZ) and Perceptive Capital Solutions (FRNM). It sold Shopify (SHOP) 57,045 shares for about $8.6M and sold Palantir (PLTR) for about $7.5M, plus other smaller trades.
3 min readSTUELPNAGEL JOHN R sold 20,000 shares of 10x Genomics, Inc. (TXG) at an average of $57.75 ($57.58–$58.72, $1.16M total) across 2 trades on 2026-08-11.
2 min readBiotech stocks moved sharply after clinical and guidance updates. Tenax Therapeutics (TENX) fell nearly 90% after its Phase 3 LEVEL trial of TNX-103 missed primary and key secondary endpoints. AbCellera Biologics (ABCL) rose on Phase 2 results for ABCL635 in menopausal vasomotor symptoms. 10x Genomics (TXG) gained after raising full-year revenue guidance and citing strong early Atera demand.
6 min readAccording to Investing.com, Cathie Wood’s ARK ETFs reported Aug. 10 trades. ARK sold 60,458 shares of Deere (DE) for about $37.53M. It bought 122,422 shares of NVIDIA (NVDA) for about $27.42M and added Broadcom (AVGO) for about $16.69M, plus Cloudflare (NET) for about $17.46M. It also sold Shopify (SHOP) and Snowflake (SNOW).
2 min read10x Genomics’ management said Atera instrument placements and related revenue are expected to ramp in Q4, constrained mainly by manufacturing capacity. It expects AI-driven biological modeling and drug discovery to support demand for single-cell and spatial technologies. Management noted Atera could temporarily cannibalize sales of Xenium and Visium, but aims for net offset. It also cited the Proteintech Genomics acquisition as a factor.
4 min read10x Genomics (TXG) reported Q2 2026 revenue of $151.0M and a net loss of $17.9M, with diluted EPS of -$0.14, versus Q2 2025 revenue of $172.9M and net income of $34.5M (EPS $0.28). Citigroup maintained a Neutral rating and raised its price target to $50. Morgan Stanley kept Neutral/Equal-Weight.
1 min read10x Genomics shares rose about 14.1% to around $52 after its Q2 report. The company posted quarterly revenue of $151.0m and a net loss of $17.9m, with EPS of -$0.14. Gross margin improved to about 74% and cash and marketable securities were $552m. Traders focused on margin and balance-sheet resilience amid declining instrument revenue.
6 min read10x Genomics (TXG) shares rose about 11.8% after its Q2 2026 results. According to the company’s earnings release, EPS was $0.28 versus a consensus loss, and revenue also beat expectations. The quarter helped offset earlier guidance that Q2 sales could decline as customers waited for Atera shipments. Full-year revenue guidance stayed at $600 million to $625 million.
4 min read
